Arjun Mohan

Dr. Arjun Mohan

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2022 in Electrochimica Acta
Verified
Journal Article
Closed access
KGKiran Kumar Garlapati
Kiran Kumar Garlapati
ANAnish R. Nath
Anish R. Nath
AMArjun Mohan
Arjun Mohan
AVAruna Vijayan
Aruna Vijayan
NSN. Sandhyarani
N. Sandhyarani

1 October 2019 in International Journal of Hydrogen Energy
Verified
Journal Article
Closed access
AMArjun Mohan
Arjun Mohan
MVMadhusudhanan Vimal
Madhusudhanan Vimal
NSNeelakandapillai Sandhyarani
Neelakandapillai Sandhyarani

11 November 2025 in Journal of Materials Chemistry A
Verified
Journal Article
Open access
PDF file
AMArjun Mohan
Arjun Mohan
MAMenon Ankitha
Menon Ankitha
MMManjusha Mathew
Manjusha Mathew
SSSanjiv Sharma
Sanjiv Sharma
PRPathath Abdul Rasheed
Pathath Abdul Rasheed
This review evaluates MXene structural integration and performance mechanisms in self-powered electrochemical sensors (SPECSs), focusing on active component function, maximum power output, long-term stability, and analytical sensitivity.

6 July 2024 in Biosensors and Bioelectronics: X
Verified
Journal Article
Open access
AMArjun Mohan
Arjun Mohan
SDSudhaunsh Deshpande
Sudhaunsh Deshpande
Tom DunlopTom Dunlop
Tom Dunlop
BNBeth Norman
Beth Norman
DODaniela Oliviera
Daniela Oliviera
SSSanjiv Sharma
Sanjiv Sharma
Phosphorylated Tau proteins are promising biomarkers for the diagnosis and prognosis of Alzheimer's disease. This study presents a novel voltametric sensor using a vanadium MXene polydopamine (VxPDA) redox active composite and a Tau-441-specific polyaniline molecularly imprinted polymer (PANI MIP) for the sensitive detection of Tau-441 in interstitial fluid (ISF) and plasma. The VxPDA/PANI MIP sensor demonstrates a broad detection range of 5 fg/mL to 5 ng/mL (122 aM/L to 122 pM/L) in ISF without the use of redox mediators, with a lower limit of detection (LOD) of 2.3 fg/mL (60 aM/L). Furthermore, a handheld device utilizing this technology successfully detects Tau-441 in artificial serum with high sensitivity (5 fg/mL to 150 fg/mL (122 aM/L to 366 aM/L)) and specificity within a clinically relevant range. The rapid detection time (∼32 min) and low cost (∼£20/device) of this sensor highlight its potential for minimally invasive, early AD diagnosis in clinical settings. This advancement aims to facilitate a transition away from invasive cerebrospinal fluid (CSF)-based diagnostic techniques for AD.

4 September 2025 in Advanced Healthcare Materials
Verified
Journal Article
Open access
SDSudhaunsh Deshpande
Sudhaunsh Deshpande
AMArjun Mohan
Arjun Mohan
GLGuoyi Liu
Guoyi Liu
KPKryztof Pawlak
Kryztof Pawlak
SSSanjiv Sharma
Sanjiv Sharma
Early diagnosis of Alzheimer's disease (AD) is hindered by the high cost, complexity, and centralization of current diagnostic platforms such as enzyme‐linked immunosorbent assay (ELISA) and single‐molecule array (SIMOA). Here, an integrated point‐of‐care (PoC) biosensing platform is reported based on redox‐active polyphenol red molecularly imprinted polymers (pPhR MIPs) deposited on highly porous gold (HPG) electrodes for the ultrasensitive, reagent‐free detection of phosphorylated tau 181 (p‐tau 181) in undiluted plasma and serum. The unique electrochemical interface combines the signal‐enhancing properties of HPG with the redox functionality of pPhR, eliminating the need for external redox probes. The resulting sensor achieves a limit of detection (LOD) of 980 fg mL −1 and sensitivity of 4.39 µA/(pg mL −1 ), rivalling high‐end lab‐based assays while operating at a fraction of the cost. The platform integrates a low‐cost, handheld potentiostat and a machine learning (ML)‐enabled web app for real‐time data classification and regression, achieving 100% classification accuracy with zero false positives or negatives. The system demonstrates compatibility with both ethylenediaminetetraacetic acid (EDTA) and heparin‐treated samples and maintains accuracy in complex matrices. This work represents a step toward World Health Organization (WHO)‐compliant, decentralized diagnostics for neurodegenerative disease, offering a scalable foundation for future multianalyte platforms targeting AD and related disorders.

22 February 2024 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
GVGeorgeta Vulpe
Georgeta Vulpe
GLGuoyi Liu
Guoyi Liu
SOSam Oakley
Sam Oakley
GYGuanghao Yang
Guanghao Yang
AMArjun Mohan
Arjun Mohan
SSSanjiv Sharma
Sanjiv Sharma
Development of wearable sensing devices for minimally invasive and real time monitoring of physiological information in ambulatory conditions.